CRISPR Medicine News, 18 November 2020 | Knockout of a novel cancer checkpoint improves solid tumour immunity - CRISPR Medicine

CRISPR-Cas9 Knockout of a Novel Cancer Checkpoint Unleashes T Cell Reactivity Against Solid Tumours

Researchers have shown that CRISPR-Cas9 knockout of CISH, a negative regulator of T cell immunity, increases the capability of T cells to fight cancer in a human clinical setting. This opens up new avenues for cancer treatment, and the novel approach to immunotherapy has already moved into a clinical trial. Read all about it here.

Career CRISPR Medicine

Thank you for now - more great reads are on the way!

And if you have questions or suggestions, you can reach out to us directly at We love hearing from readers!

Happy Reading!


p.s. You can follow CRISPR Medicine News on Twitter and LinkedIn. If someone forwarded this email to you, you can sign up for our newsletter yourself here.